V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20213668 | 20080073 | null | 83.25 | 02 | 2018-01-11 | 2018-01-31 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 101486632 |
| 20213669 | 20080074 | 1.73 | 80 | Disease modification (D) | 2019-06-15 | 2019-06-28 | HCX (Cape + Cisp + Tras) - Load | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100531268 |
| 20213670 | 20080075 | 1.68 | 0 | Disease modification (D) | 2018-04-27 | 2018-05-02 | LANREOTIDE | 02 | N | LANREOTIDE | 101119648 |
| 20213671 | 20080076 | 1.67 | 80.5 | Palliative (P) | 2020-02-13 | 2020-02-21 | Cape+Cisplatin+Trastuzumab Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101842162 |
| 20213672 | 20080077 | 1.52 | 63.75 | Palliative (P) | 2018-01-08 | 2018-01-17 | HCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101766472 |
| 20213675 | 20080079 | 1.67 | 58.3 | Palliative (P) | 2019-08-04 | 2019-08-14 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101677281 |
| 20213677 | 20080080 | 1.82 | null | Palliative (P) | 2018-05-28 | 2018-05-28 | LANREOTIDE | 02 | N | LANREOTIDE | 100926028 |
| 20213678 | 20080081 | 1.67 | 73.4 | Curative (C) | 2016-07-02 | 2016-07-22 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 101355928 |
| 20213679 | 20080082 | 1.6 | 52.4 | Curative (C) | 2018-07-29 | 2018-08-09 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100847309 |
| 20213680 | 20080083 | 1.78 | 74.9 | Palliative (P) | 2016-12-05 | 2016-12-05 | LANREOTIDE | 02 | N | LANREOTIDE | 101055985 |
| 20213681 | 20080084 | 1.71 | 67.8 | Neo-adjuvant (N) | 2019-07-12 | 2019-07-19 | Trial Unspecified | 01 | N | TRIAL | 101060283 |
| 20213683 | 20080085 | 1.75 | 92.6 | Adjuvant (A) | 2016-10-01 | 2016-10-01 | IMATINIB | 02 | N | IMATINIB | 100904315 |
| 20213684 | 20080086 | 1.6 | 40.2 | Palliative (P) | 2018-05-20 | 2018-05-20 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100524378 |
| 20213687 | 20080088 | 0 | null | Neo-adjuvant (N) | 2019-02-28 | 2019-03-26 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 101609288 |
| 20213688 | 20080089 | 1.65 | 61 | Palliative (P) | 2019-02-03 | 2019-02-24 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101814265 |
| 20213689 | 20080090 | 1.6 | 49.3 | null | 2016-03-06 | 2016-04-04 | Cape+Cisplatin+Trastuzumab Load | 02 | null | TRIAL | 101601514 |
| 20213690 | 20080091 | null | null | 03 | 2022-04-10 | 2022-04-28 | HCX (Cape + Cisp + Tras) - Main | 02 | N | LANREOTIDE | 101819708 |
| 20213691 | 20080092 | 0 | 108.5 | 03 | 2018-09-24 | 2018-10-16 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 100447855 |
| 20213692 | 20080093 | 1.79 | 92.3 | Palliative (P) | 2016-09-23 | 2016-10-08 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101375403 |
| 20213694 | 20080095 | 1.65 | 0 | Palliative (P) | 2019-10-30 | 2019-10-30 | Imatinib 400mg | 02 | N | IMATINIB | 100320276 |
| 20213696 | 20080096 | 1.6 | 61.8 | Palliative (P) | 2018-11-10 | 2018-11-12 | GO2 TRIAL | 1 | N | TRIAL | 101826619 |
| 20213697 | 20080097 | 1.64 | null | Curative (C) | 2018-05-08 | 2018-06-17 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100147694 |
| 20213699 | 20080099 | 1.6 | 62.5 | Curative (C) | 2019-01-02 | 2019-01-21 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101061127 |
| 20213700 | 20080100 | null | 83.2 | Palliative (P) | 2017-07-07 | 2017-07-21 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 100951369 |
| 20213701 | 20080101 | 1.77 | 74 | Palliative (P) | 2018-03-11 | 2018-03-11 | Trial Unspecified | Y | N | TRIAL | 101077532 |
| 20213703 | 20080102 | 1.73 | 70 | Palliative (P) | 2021-02-11 | 2021-02-25 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100628835 |
| 20213704 | 20080103 | 1.7 | 58.9 | Curative (C) | 2018-04-20 | 2018-04-24 | Fluorouracil+Mitomycin+RT (Bladder) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101864931 |
| 20213705 | 20080104 | 1.7 | 66 | Neo-adjuvant (N) | 2018-12-02 | 2018-12-03 | IMATINIB | N | N | IMATINIB | 100023179 |
| 20213707 | 20080105 | 1.73 | 88.8 | Palliative (P) | 2016-08-29 | 2016-09-12 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101131647 |
| 20213708 | 20080106 | 1.6 | 67.2 | Palliative (P) | 2016-04-08 | 2016-04-22 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100603001 |
| 20213709 | 20080107 | 1.6 | 79.3 | Curative (C) | null | 2017-06-23 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100297665 |
| 20213711 | 20080109 | 1.81 | 88 | Palliative (P) | 2019-02-18 | 2019-03-29 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100086572 |
| 20213712 | 20080110 | 1.62 | 74.6 | Palliative (P) | 2018-02-28 | 2018-03-16 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101365598 |
| 20213713 | 20080111 | 1.45 | 61.1 | Palliative (P) | 2016-08-15 | 2016-08-28 | Cape+Cisplatin+Trastuzumab Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101393570 |
| 20213715 | 20080112 | 1.6 | null | Curative (C) | null | 2017-10-02 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 101729003 |
| 20213717 | 20080114 | 1.63 | 60.7 | null | 2020-02-16 | 2020-03-08 | Cape+Cisplatin+Trastuzumab Load | 02 | null | LANREOTIDE | 101017893 |
| 20213718 | 20080115 | null | 56.3 | null | 2018-01-10 | 2018-01-10 | LANREOTIDE | 02 | null | LANREOTIDE | 100581873 |
| 20213719 | 20080116 | 1.56 | 66.8 | Curative (C) | 2017-04-13 | 2017-05-03 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100856487 |
| 20213721 | 20080117 | 1.68 | 48 | Palliative (P) | 2017-08-16 | 2017-09-11 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100643083 |
| 20213722 | 20080118 | 1.7 | 54 | Palliative (P) | 2018-06-08 | 2018-06-28 | HCX (Cape + Cisp + Tras) - Load | 02 | N | TRIAL | 100382193 |
| 20213723 | 20080119 | 1.6 | 77 | Curative (C) | 2016-07-09 | 2016-07-09 | Trial Unspecified | Y | N | TRIAL | 100344167 |
| 20213725 | 20080120 | 1.68 | 44 | Palliative (P) | null | 2016-04-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100768604 |
| 20213727 | 20080122 | 1.8 | 66.9 | null | 2016-07-16 | 2016-08-09 | Cape+Cisplatin+Trastuzumab Load | 02 | null | LANREOTIDE | 100866031 |
| 20213728 | 20080123 | 1.96 | 0 | Palliative (P) | 2016-10-11 | 2016-10-21 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100849181 |
| 20213729 | 20080124 | 1.8 | 92.6 | Curative (C) | 2016-06-04 | 2016-06-07 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100043133 |
| 20213730 | 20080125 | 1.6 | 78.4 | Not known (9) | 2018-11-06 | 2018-11-12 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100912998 |
| 20213732 | 20080127 | 0 | 77.4 | Palliative (P) | 2017-09-27 | 2017-09-27 | IMATINIB | 02 | N | IMATINIB | 100909771 |
| 20213733 | 20080128 | 0 | null | 02 | 2017-08-17 | 2017-09-06 | Cape+Cisplatin+Trastuzumab Main | 02 | N | LANREOTIDE | 100295341 |
| 20213734 | 20080129 | 1.7 | 84.2 | Curative (C) | 2019-09-14 | 2019-09-14 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 101426541 |
| 20213736 | 20080130 | 1.8 | 58.05 | Palliative (P) | 2019-03-11 | 2019-03-31 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101064491 |